School of Materials and Chemistry, Institute of Bismuth and Rhenium, University of Shanghai for Science and Technology, Shanghai, China.
Department of Limb Trauma, Wendeng Orthopaedic Hospital of Shandong Province, Weihai, Shandong, China.
Front Immunol. 2024 Mar 11;15:1374506. doi: 10.3389/fimmu.2024.1374506. eCollection 2024.
Pulmonary hypertension (PH) is a malignant disease with progressive increase of pulmonary vascular pressure, which eventually leads to right heart failure. More and more evidences show that immune cells and inflammation play an important role in the occurrence and development of PH. In the context of pulmonary vascular diseases, immune cells migrate into the walls of the pulmonary vascular system. This leads to an increase in the levels of cytokines and chemokines in both the bloodstream and the surrounding tissues of the pulmonary vessels. As a result, new approaches such as immunotherapy and anti-inflammatory treatments are being considered as potential strategies to halt or potentially reverse the progression of PH. We reviewed the potential mechanisms of immune cells, cytokines and chemokines in PH development. The potential relationship of vascular cells or bone morphogenetic protein receptor 2 (BMPR2) in immune regulation was also expounded. The clinical application and future prospect of immunotherapy were further discussed.
肺动脉高压(PH)是一种以肺血管压力进行性升高为特征的恶性疾病,最终可导致右心衰竭。越来越多的证据表明,免疫细胞和炎症在 PH 的发生和发展中起着重要作用。在肺血管疾病的背景下,免疫细胞迁移到肺血管系统的壁中。这导致细胞因子和趋化因子在血流和肺血管周围组织中的水平增加。因此,免疫疗法和抗炎治疗等新方法被认为是阻止或可能逆转 PH 进展的潜在策略。我们综述了免疫细胞、细胞因子和趋化因子在 PH 发展中的潜在机制。还阐述了血管细胞或骨形态发生蛋白受体 2(BMPR2)在免疫调节中的潜在关系。进一步讨论了免疫疗法的临床应用和未来前景。